Ontology type: schema:ScholarlyArticle
2012-07-05
AUTHORSF J Giles, P D le Coutre, J Pinilla-Ibarz, R A Larson, N Gattermann, O G Ottmann, A Hochhaus, J P Radich, G Saglio, T P Hughes, G Martinelli, D-W Kim, S Novick, K Gillis, X Fan, J Cortes, M Baccarani, H M Kantarjian
ABSTRACTNilotinib (Tasigna) is a BCR–ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant of or resistant to imatinib. The 48-month follow-up data for patients with CML-CP treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. Overall, 59% of patients achieved major cytogenetic response; 45% achieved complete cytogenetic response while on study. The estimated rate of overall survival (OS) and progression-free survival (PFS) at 48 months was 78% and 57%, respectively. Deeper levels of molecular responses at 3 and 6 months were highly positively correlated with long-term outcomes, including PFS and OS at 48 months. Of the 321 patients initially enrolled in the study, 98 (31%) were treated for at least 48 months. Discontinuations were primarily due to disease progression (30%) or adverse events (21%). Nilotinib is safe and effective for long-term use in responding patients with CML-CP who are intolerant of or resistant to imatinib. Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib. More... »
PAGES107-112
http://scigraph.springernature.com/pub.10.1038/leu.2012.181
DOIhttp://dx.doi.org/10.1038/leu.2012.181
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1028369333
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/22763385
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Benzamides",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Resistance, Neoplasm",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Imatinib Mesylate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "International Agencies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid, Chronic-Phase",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Maximum Tolerated Dose",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Piperazines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prognosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrimidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland",
"id": "http://www.grid.ac/institutes/grid.8217.c",
"name": [
"HRB Clinical Research Facilities, National University of Ireland Galway and Trinity College, Dublin, Ireland"
],
"type": "Organization"
},
"familyName": "Giles",
"givenName": "F J",
"id": "sg:person.010046107662.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010046107662.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Oncology, Charit\u00e9-Humboldt-Universit\u00e4t, Campus Virchow Klinikum, Berlin, Germany",
"id": "http://www.grid.ac/institutes/grid.6363.0",
"name": [
"Department of Hematology and Oncology, Charit\u00e9-Humboldt-Universit\u00e4t, Campus Virchow Klinikum, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "le Coutre",
"givenName": "P D",
"id": "sg:person.01344447222.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA",
"id": "http://www.grid.ac/institutes/grid.468198.a",
"name": [
"H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA"
],
"type": "Organization"
},
"familyName": "Pinilla-Ibarz",
"givenName": "J",
"id": "sg:person.01214300454.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214300454.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Chicago, Chicago, IL, USA",
"id": "http://www.grid.ac/institutes/grid.170205.1",
"name": [
"University of Chicago, Chicago, IL, USA"
],
"type": "Organization"
},
"familyName": "Larson",
"givenName": "R A",
"id": "sg:person.011155432117.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011155432117.78"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "N",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany",
"id": "http://www.grid.ac/institutes/grid.411088.4",
"name": [
"Department of Medicine, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany"
],
"type": "Organization"
},
"familyName": "Ottmann",
"givenName": "O G",
"id": "sg:person.01051501512.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Oncology, Universit\u00e4tsklinikum Jena, Jena, Germany",
"id": "http://www.grid.ac/institutes/grid.275559.9",
"name": [
"Department of Hematology and Oncology, Universit\u00e4tsklinikum Jena, Jena, Germany"
],
"type": "Organization"
},
"familyName": "Hochhaus",
"givenName": "A",
"id": "sg:person.01064615503.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA",
"id": "http://www.grid.ac/institutes/grid.270240.3",
"name": [
"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
],
"type": "Organization"
},
"familyName": "Radich",
"givenName": "J P",
"id": "sg:person.011362420057.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Cellular Biotechnologies and Hematology, University at Orbassano, Turin, Italy"
],
"type": "Organization"
},
"familyName": "Saglio",
"givenName": "G",
"id": "sg:person.01334477453.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia",
"id": "http://www.grid.ac/institutes/grid.414733.6",
"name": [
"Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia"
],
"type": "Organization"
},
"familyName": "Hughes",
"givenName": "T P",
"id": "sg:person.014243130677.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014243130677.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy",
"id": "http://www.grid.ac/institutes/grid.6292.f",
"name": [
"Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy"
],
"type": "Organization"
},
"familyName": "Martinelli",
"givenName": "G",
"id": "sg:person.012171410322.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012171410322.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Seoul St Mary\u2019s Hospital, Seoul, Korea",
"id": "http://www.grid.ac/institutes/grid.414966.8",
"name": [
"Seoul St Mary\u2019s Hospital, Seoul, Korea"
],
"type": "Organization"
},
"familyName": "Kim",
"givenName": "D-W",
"id": "sg:person.013164724220.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013164724220.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
],
"type": "Organization"
},
"familyName": "Novick",
"givenName": "S",
"id": "sg:person.0753016076.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753016076.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
],
"type": "Organization"
},
"familyName": "Gillis",
"givenName": "K",
"id": "sg:person.01021131276.58",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021131276.58"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
],
"type": "Organization"
},
"familyName": "Fan",
"givenName": "X",
"id": "sg:person.01272366376.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272366376.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Cortes",
"givenName": "J",
"id": "sg:person.016160407152.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016160407152.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy",
"id": "http://www.grid.ac/institutes/grid.6292.f",
"name": [
"Department of Hematology/Oncology L and A Seragnoli, University of Bologna, Bologna, Italy"
],
"type": "Organization"
},
"familyName": "Baccarani",
"givenName": "M",
"id": "sg:person.01016466503.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA",
"id": "http://www.grid.ac/institutes/grid.240145.6",
"name": [
"Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Kantarjian",
"givenName": "H M",
"id": "sg:person.07607502677.73",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07607502677.73"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/leu.2012.134",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042361347",
"https://doi.org/10.1038/leu.2012.134"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2009.38",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002899527",
"https://doi.org/10.1038/leu.2009.38"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nm0596-561",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051513257",
"https://doi.org/10.1038/nm0596-561"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2010.110",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016924943",
"https://doi.org/10.1038/leu.2010.110"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2011.323",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050607241",
"https://doi.org/10.1038/leu.2011.323"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2012.85",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006724216",
"https://doi.org/10.1038/leu.2012.85"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2008.84",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024891930",
"https://doi.org/10.1038/leu.2008.84"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2011.355",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045865761",
"https://doi.org/10.1038/leu.2011.355"
],
"type": "CreativeWork"
}
],
"datePublished": "2012-07-05",
"datePublishedReg": "2012-07-05",
"description": "Nilotinib (Tasigna) is a BCR\u2013ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant of or resistant to imatinib. The 48-month follow-up data for patients with CML-CP treated with nilotinib after imatinib resistance or intolerance on an international phase II study were analyzed. Overall, 59% of patients achieved major cytogenetic response; 45% achieved complete cytogenetic response while on study. The estimated rate of overall survival (OS) and progression-free survival (PFS) at 48 months was 78% and 57%, respectively. Deeper levels of molecular responses at 3 and 6 months were highly positively correlated with long-term outcomes, including PFS and OS at 48 months. Of the 321 patients initially enrolled in the study, 98 (31%) were treated for at least 48 months. Discontinuations were primarily due to disease progression (30%) or adverse events (21%). Nilotinib is safe and effective for long-term use in responding patients with CML-CP who are intolerant of or resistant to imatinib. Further significant improvements in therapy are required for patients who are resistant or intolerant to imatinib.",
"genre": "article",
"id": "sg:pub.10.1038/leu.2012.181",
"isAccessibleForFree": false,
"isFundedItemOf": [
{
"id": "sg:grant.2438826",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1097065",
"issn": [
"0887-6924",
"1476-5551"
],
"name": "Leukemia",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "27"
}
],
"keywords": [
"progression-free survival",
"phase II study",
"chronic myeloid leukemia",
"overall survival",
"CML-CP",
"II study",
"cytogenetic response",
"chronic phase",
"myeloid leukemia",
"Philadelphia chromosome-positive chronic myeloid leukemia",
"BCR-ABL1 tyrosine kinase inhibitors",
"international phase II study",
"chromosome-positive chronic myeloid leukemia",
"imatinib-intolerant patients",
"major cytogenetic response",
"complete cytogenetic response",
"long-term outcomes",
"treatment of patients",
"tyrosine kinase inhibitors",
"long-term use",
"adverse events",
"disease progression",
"imatinib resistance",
"patients",
"nilotinib",
"kinase inhibitors",
"months",
"leukemia",
"follow",
"further significant improvement",
"survival",
"molecular response",
"significant improvement",
"discontinuation",
"response",
"therapy",
"intolerance",
"study",
"progression",
"outcomes",
"treatment",
"inhibitors",
"levels",
"rate",
"events",
"resistance",
"improvement",
"use",
"data",
"results",
"phase",
"deep levels"
],
"name": "Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study",
"pagination": "107-112",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1028369333"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/leu.2012.181"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"22763385"
]
}
],
"sameAs": [
"https://doi.org/10.1038/leu.2012.181",
"https://app.dimensions.ai/details/publication/pub.1028369333"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:00",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_581.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/leu.2012.181"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/leu.2012.181'
This table displays all metadata directly associated to this object as RDF triples.
393 TRIPLES
21 PREDICATES
107 URIs
91 LITERALS
29 BLANK NODES